HyperSight Imaging for Cancer
Trial Summary
Do I need to stop my current medications for the HyperSight Imaging trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment HyperSight Imaging for cancer?
The research shows that HyperSight Imaging, a type of cone beam computed tomography (CBCT), provides high-quality images quickly, which can be useful in guiding cancer treatments. This technology is also being used in other medical procedures due to its ability to offer detailed images, suggesting it could be effective in cancer treatment as well.12345
Is HyperSight Imaging generally safe for humans?
How is the HyperSight Imaging treatment different from other cancer treatments?
What is the purpose of this trial?
The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues. Image-guided radiation therapy (IGRT) involves acquiring cone beam computed tomography (CBCT) scans just before or during treatment sessions. By comparing the CBCT images with the reference images from the treatment planning process, clinicians can make necessary adjustments to ensure precise targeting and account for any changes that may have occurred since the initial planning. Conventional CBCT technology is, however, limited by several factors including long acquisition times that result in motion artifacts in the image, smaller fields of view that limit the volume of anatomy that can be imaged, poor image quality that limits soft tissue visibility, and artifacts created by dense metal implants. This study will evaluate a novel CBCT imaging solution ("HyperSight") that has the potential to address the challenges of conventional CBCT.
Eligibility Criteria
This trial is for individuals with various cancers (pelvic, head and neck, breast, lung, gastric, gastrointestinal tumors) who require precise radiation therapy. Participants should need image-guided radiation treatment but are not specified by other inclusion or exclusion criteria in the provided information.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging Evaluation
Subjects are imaged with the new HyperSight CBCT imaging system to evaluate image quality, noise, and artifact levels compared to conventional CT imaging.
Follow-up
Participants are monitored for safety and effectiveness of the HyperSight imaging system, including patient experience and breath hold tolerance.
Treatment Details
Interventions
- HyperSight Imaging
Find a Clinic Near You
Who Is Running the Clinical Trial?
Varian, a Siemens Healthineers Company
Lead Sponsor